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Richmond, VA 23298, USABackground & Aims: The lack of a preclinical model of progres-
sive non-alcoholic steatohepatitis (NASH) that recapitulates
activated in these mice. The HCC gene signature resembled the
S1 and S2 human subclasses of HCC (FDR 0.01 for both). Onlyhuman disease is a barrier to therapeutic development.
Methods: A stable isogenic cross between C57BL/6J (B6) and
129S1/SvImJ (S129) mice were fed a high fat diet with ad libitum
consumption of glucose and fructose in physiologically relevant
concentrations and compared to mice fed a chow diet and also
to both parent strains.
Results: Following initiation of the obesogenic diet, B6/129 mice
developed obesity, insulin resistance, hypertriglyceridemia and
increased LDL-cholesterol. They sequentially also developed
steatosis (4–8 weeks), steatohepatitis (16–24 weeks), progressive
fibrosis (16 weeks onwards) and spontaneous hepatocellular can-
cer (HCC). There was a strong concordance between the pattern
of pathway activation at a transcriptomic level between humans
and mice with similar histological phenotypes (FDR 0.02 for early
and 0.08 for late time points). Lipogenic, inflammatory and apop-
totic signaling pathways activated in human NASH were alsoJournal of Hepatology 20
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these aspects of human NAFLD.
Conclusions:We here describe a diet-induced animal model of
non-alcoholic fatty liver disease (DIAMOND) that recapitulates
the key physiological, metabolic, histologic, transcriptomic and
cell-signaling changes seen in humans with progressive NASH.
Lay summary:We have developed a diet-induced mouse model
of non-alcoholic steatohepatitis (NASH) and hepatic cancers in
a cross between two mouse strains (129S1/SvImJ and C57Bl/6J).
This model mimics all the physiological, metabolic, histological,
transcriptomic gene signature and clinical endpoints of human
NASH and can facilitate preclinical development of therapeutic
targets for NASH.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Introduction
Non-alcoholic fatty liver disease (NAFLD) has emerged as the
leading cause of chronic liver disease in most parts of the
Western world. NAFLD includes both a fatty liver and steatohep-
atitis which can progress through stages of fibrosis to cirrhosis
and can be complicated by hepatocellular cancer [1]. There is cur-
rently no approved therapy for NASH.
There is a need to create animal models that recapitulate the
physiology, histology, outcomes and transcriptomic changes seen
in humans with NASH. While a large number of models have
been described, they have several limitations [2] (Supplementary
Table 1). These models are dissimilar to human NASH by either
requiring specific gene knockout, non-physiological dietary
manipulations or their lack of insulin resistance or liver histology16 vol. 65 j 579–588
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typical of human NASH [3]. Importantly, most models do not
develop progressive fibrosis and do not lead to hepatocellular
cancer [2,4]. While the Ossabaw pig develops lesions very consis-
tent with human NASH [5], the cost and resources needed to use
this model renders it challenging for widespread use. The
C57BL/6J mice fed a high fat, high sugar diet develop steatohep-
atitis with fibrosis [6]. However, the severity of fibrosis is mild
and the disease is not complicated by hepatocellular cancer, an
increasingly recognized and clinically important end-point of
the progression of NASH.
An ideal preclinical model for NASH should be relatively sim-
ple, triggered by the same causes as human disease (caloric
excess), associated with the same risk factors as in humans
(obesity, insulin resistance and dyslipidemia), and it should
match human disease with respect to metabolic features, histol-
ogy, outcomes, gene expression signature, lipid accumulation and
activation of pathways relevant in humans. Importantly, it should
also recapitulate the various histological stages of human disease.
The development of hepatocellular carcinoma (HCC) in this set-
ting should also be triggered by the disease state and not by
administration of a chemical carcinogen. We here report a
diet-induced animal model of non-alcoholic fatty liver disease
(DIAMOND) using an isogenic strain derived from a cross of
two common mouse strains, 129S1/SvImJ and C57BL/6J where a
simple high fat diet accompanied by ad libitum consumption of
water with a high fructose and glucose content (Western diet
sugar water (WD SW)) sequentially induces steatosis, steatohep-
atitis, progressive fibrosis and HCC. The phenotype was noted
serendipitously and refined to develop the isogenic strain and
the dietary manipulations to reproducibly produce the disease
phenotype.300
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Fig. 1. DIAMOND mice develop obesity, liver injury, dyslipidemia and insulin resistan
Western Diet (WD SW) for up to 52 weeks. (A) Body weight change over time, (B) Liver w
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Animals
A unique, isogenic mouse strain derived from a C57BL/6J and 129S1/SvImJ back-
ground (B6/129) was created and maintained with inbreeding. Additional infor-
mation on B6/129 origin are described in the Supplementary materials and
methods section. Pure C57BL/6J (B6) or 129S1/SvImJ (S129) were purchased from
Jackson Laboratory (Bar Harbor) and used as controls. All mice were housed in a
12 h light–12 h dark cycle in a 21–23 C facility and were euthanized at varying
time points following initiation of dietary intervention. All procedures were per-
formed according to protocols approved by the Animal Care and Use Committee
of Virginia Commonwealth University (IACUC AM 10154).
Dietary interventions
Male mice (8–12 weeks of age) were fed ad libitum a high fat diet, high carbohy-
drate diet (Western diet, WD) with 42% kcal from fat and containing 0.1%
cholesterol (Harlan TD.88137) with a high fructose-glucose solution (SW,
23.1 g/L d-fructose + 18.9 g/L d-glucose), as previously described [6]. Control mice
were fed a standard chow diet (CD, Harlan TD.7012) with normal water (NW).
Histological analysis
Liver histology was assessed using hematoxylin and eosin (H&E) stains in
paraffin-embedded sections using standard commercially used methods. Fibrosis
was assessed using both Masson’s trichrome and Sirius Red stains in paraffin-
embedded sections using established methodology [7]. The presence of steatosis
was further confirmed used Oil-Red-O stains in frozen sections using standard
methods [8]. The liver histology was evaluated by an expert liver pathologist
(PB) who was blinded to the dietary condition. Histology was assessed using
the NASH CRN and fatty liver inhibition of progression (FLIP) consortia criteria
(see the Supplementary materials and methods section for details) [3].
A detailed description of biochemical, molecular, transcriptomic, bioinfor-
matics and statistical analysis is also provided in the Supplementary materials
and methods section.300
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Results
The genetic background of the mouse
Following repeated brother-sister mating of the C57BL/6J;129S1/
SvImJ mice (B6/129) over a four-year time frame, it was observed
that the histological phenotype of steatohepatitis could be
obtained consistently. A set of 158 single nucleotide polymor-
phisms (SNPs) that included both specific C57BL/6 and 129S1
SNPs was tested in a random set of six mice (Supplementary
Table 2). These demonstrated that approximately 60% of the SNPs
were of C57BL/6 origin while the rest were of 129S1 origin.
Importantly, all mice were genetically identical confirming the
isogenic nature of the strain. The mice have been re-derived
and their genotype and phenotype were found to be maintained.
DIAMOND mice develop obesity, liver injury, dyslipidemia and
insulin resistance
B6/129 mice fed a WD SW developed rapid weight gain and obe-
sity compared to CD NW-fed control mice (Fig. 1A). This wasCD NW WD SW CD NW WD SW
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Fig. 2. DIAMONDmice sequentially develop a fatty liver, steatohepatitis, advanced fib
or high fructose/glucose, high fat Western Diet (WD SW) for 8 (a, b), 16–24 (c, d) and 5
tumors were observed at the time of necropsy (h–j) as compared to CD NW mice (g); ar
from CD NW or WD SW mice at 8 (a, d, g, j), 16–24 (b, e, h, k) or 52 weeks (c, f, i, l) of
Picrosirius Red (g–l) are shown. Original magnification, 20. (C) Histology score for st
fibrosis were quantified. Data are expressed as the mean ± SEM for 6–10 mice per group;
(b) staining of liver tissue from mice fed a WD SW for 52 weeks depicting the individ
ballooning, (c) Mallory-Denk bodies (MDB), (d) lobular inflammation and (e) apoptot
hepatocytes (as indicated by small arrow), whereas in ballooned hepatocyte (as indicate
cytoplasm is noted. Lipid vacuoles are indicated by a star. Original magnification, 40.
Journal of Hepatology 201accompanied by an increase in liver weight at all time points
(data for weeks 8 and 52 shown in Fig. 1B). Feeding a WD SW
diet also led to a significant increase in AST and ALT which per-
sisted up to 52 weeks of diet administration (Fig. 1C). Mice fed
a WD SW diet also developed an increase in total cholesterol
and LDL-cholesterol (LDL-c), as it has been reported in humans
with NASH [9]. Hypertriglyceridemia also developed in these
mice and was maximal at 8 weeks (Fig. 1D). At week 52, LDL-c
remained significantly elevated while the hypertriglyceridemia
declined to values noted in CD NW-fed mice.
Insulin resistance was assessed using an insulin tolerance test
(ITT). Although WD SW-fed mice remained initially insulin sensi-
tive at 8 weeks, they developed significant insulin resistance at
16 weeks which was sustained up to 52 weeks (Figs. 1E, 7B).
On a separate day, a glucose tolerance test (GTT) was also per-
formed. While glucose levels were often higher following intra-
peritoneal glucose administration in mice fed WD SW (Fig. 1F),
these differences did not reach statistical significance. This sug-
gested that despite insulin resistance, the mice still had enough
pancreatic islet b cell reserve to be able to mount a gluco-
regulatory insulin response after a glucose challenge. There wasCD NW Tumors at 52 wk
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Fig. 3. Main histological features of DIAMONDmice are comparable to human
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also a trend towards decreased circulating adiponectin 8 weeks
after WD SW initiation which remained relatively unchanged
thereafter (Supplementary Fig. 1). Thus, these results indicate
that B6/129 mice fed a WD SW diet develop obesity, dyslipi-
demia, liver injury and insulin resistance.
DIAMOND mice sequentially develop a fatty liver, steatohepatitis and
advanced fibrosis
Within 4–8 weeks of WD SW administration, the liver became
tan and visibly lighter in color compared to CD NW-fed mice
and this was maintained at 16–24 and 52 weeks (Fig. 2A). At
week 52, the surface of the liver demonstrated nodularity in
some but not in all mice and multiple foci of tumors with hemor-
rhage within some of the larger tumors were seen at the time of
necropsy.
Liver histology indicated that all WD SW-fed mice developed
extensive macrovesicular and small droplet steatosis by week 8
(Fig. 2 and Supplementary Fig. 2). The latter were seen most com-
monly in zone 3. Most mice had grade 3 steatosis at 8 weeks but
this declined after 32 weeks. These findings were confirmed by
Oil-Red-O staining and by direct triglyceride quantification
(Supplementary Fig. 2).
Steatohepatitis developed in an increasing proportion of mice
after week 8 and became pronounced after 16–24 weeks follow-
ing initiation of WD SW diet. This was characterized by steatosis,
lobular inflammation and hepatocellular ballooning some with
Mallory-Denk bodies (MDB) (Fig. 2B–D). Histologically, the bal-
looning, Mallory-Denk bodies and apoptotic cells were as typi-
cally described in the literature and comparable to human
NASH (Figs. 2D and 3). In contrast to the decrease in steatosis,
ballooning and inflammation were prominent at week 52.
Cytokeratin-18 (CK-18) stains revealed normal staining in histo-
logically normal hepatocytes and clearing within ballooned cells
as described in humans (Fig. 2D) [10].
The NAFLD activity score (NAS) increased by week 8 and
remained significantly higher than chow-fed mice by week 52
(Fig. 2C). At earlier time points, steatosis contributed dispropor-
tionately to the NAS while at late time points, inflammation
and ballooning were the major contributors.
Pericellular stage 1 sinusoidal fibrosis, as assessed by Sirius
Red staining, was present by weeks 16–24 after initiation of the
WD SW diet, with also stage 2 fibrosis observed in some mice.
Fibrosis increased progressively and by week 52, severe bridging
fibrosis was noted in the majority of mice with early nodule for-
mation in some (Figs. 2B, 3 and Supplementary Fig. 3A). The
fibrosis pattern resembled that seen in humans with stages 1–3
patterns of fibrosis identified in the mice (Fig. 3). Collagen fibrils
could be seen in the sinusoids at high magnification and the acti-
vation of fibrogenesis was further confirmed by a-smooth muscle
actin and desmin stains (Supplementary Fig. 3B, C) [11]. Quanti-
tative morphometry further demonstrated that the collagen pro-
portional area increased to 2.3 ± 0.4% by week 52 in WD SW-fed
mice. Collectively, these results indicate that B6/129 mice fed a
WD SW diet sequentially developed steatosis, steatohepatitis
and progressive fibrosis (16 weeks onwards).
Activation of signaling pathways relevant to human NASH
Increased lipogenic-, inflammatory- and pro-apoptotic signaling
are hallmarks of NASH in humans [12–14]. At both weeks 8582 Journal of Hepatology 201and 52, there was a significant increase in expression of fatty acid
synthetase (FAS) as well as acetyl CoA carboxylase (ACC)
(Fig. 4A). Endoplasmic reticulum (ER) stress was evident in the
livers fromWD SW-fed mice with the detection of an active phos-
phorylation of PERK by 8 weeks and increased CHOP mRNA
expression at later time point (52 weeks) (Supplementary
Fig. 4A, B). However, IRE-1 activity as assessed by Xbp-1 splicing
remained unchanged by high fat diet throughout the time course
of the unfolded protein response (UPR) (Supplementary Fig. 4C).
Phosphorylated and activated JNK, a key mediator of inflamma-
tion in human NASH [12,15], significantly increased after week
8 up to week 52. Activation of apoptotic signaling relevant to6 vol. 65 j 579–588
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JOURNAL OF HEPATOLOGYhuman NASH and lipotoxicity [16,17] via increased expression in
pro-apoptotic proteins BIM and p53 upregulated modulator of
apoptosis (PUMA), and cleaved poly ADP ribose polymerase
(PARP) and caspase 3 was observed at later time points (data
for week 52 shown in Fig. 4A).
DIAMOND mice have a transcriptomic profile similar to humans with
NASH
Volcano plot and heat map visualization of the hepatic transcrip-
tome demonstrated distinct differences between CD NW-fed and
WD SW-fed mouse at 8 weeks (Fig. 4B, C). The separation of gene
expression profile was further confirmed by principal component
analysis. There was also a remarkable similarity in gene expres-
sion signatures from one mouse to the other within each exper-
imental group. Gene OntologyTM evaluation indicated a major
effect of genes involved in multiple metabolic processes by week
8 in WD SW-fed mice (Fig. 4D). Gene Set Enrichment Analysis,
based on a priori defined sets of genes along specific pathways,
demonstrated multiple pathways that were differentially
activated with blood coagulation, TGF-b-Wnt, cytoskeletal
remodeling and LRRK2 in Parkinsons disease as the top four path-
ways based on statistical significance (Fig. 4E and Supplementary
Fig. 5). There was also evidence for increased apoptotic and
inflammatory signaling pathway activation at a transcriptional
level. Biological networks activated by WD SW was furtherJournal of Hepatology 201determined (Fig. 4F) in an unbiased manner using the Analyze
Networks algorithm [18,19]. A b-catenin, JAK2, SMAD3, TGF-b
receptor type II, ILK network that impacts cell proliferation, reg-
ulation of phosphorylation and macromolecule metabolic pro-
cesses was the principal network upregulated by WD SW at
8 weeks (Supplementary Table 3).
The hepatic gene expression at a late time point (week 52)
was also different from CD NW-fed mice for the same duration
(Fig. 5A–D). In contrast to the changes seen at 8 weeks, there
was increased transcriptional activation of oxidative stress,
innate immune system and inflammatory pathways at 52 weeks
(Fig. 5A–D). This is consistent with data on these pathways in dis-
ease progression in humans with NASH [20,21]. Gene ontology
(GO) and process networks analysis also identified activation of
multiple inflammatory processes with disease progression
(Fig. 5A, C). While the metabolic pathway changes noted at
8 weeks were still altered at 52 weeks, they were less prominent.
The hepatic transcriptome of the B6/129 mice was compared
to an existing data set of human controls and non-cirrhotic NASH
(41 normal/healthy obese and 18 NASH patients) [22]. A strong
concordance of the mouse gene expression patterns at 8 and
52 weeks to the human NASH transcriptome was observed
(FDR 0.02 and 0.08, respectively) (Fig. 5E). When compared to
human cirrhosis of varied etiologies including NASH (186-gene
signature, including 73 poor prognosis-correlated and 113 good
prognosis-correlated genes) [23,24], the pattern of gene6 vol. 65 j 579–588 583
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Fig. 5. Hepatic gene expression dataset in DIAMOND mice at 52 weeks concords with a human liver cirrhosis and NASH-associated gene signature. Transcriptome
analysis was performed on liver tissues from B6/129 mice fed a chow diet (CD NW) or a high fructose/glucose, high fat Western diet (WD SW) mice for 52 weeks (A-F) and
8 weeks (E) (n = 5 per group). (A) Gene ontology (GO) processes; (B) Gene set Enrichment Analysis (GSEA); (C) Process Networks analysis. The top rank ordered processes,
maps and networks are based on statistical significance; (D) Heat map demonstrating deregulated genes. Red and blue colors indicate high and low gene expression,
respectively. (E) Similarity between global liver transcriptome of mice fed a WD SW for 8 or 52 weeks and global liver transcriptome in liver biopsy tissues from 18 human
NASH patients and 41 normal/healthy obese individuals using subclass mapping algorithm (see Supplementary materials and methods). Numbers on heat map indicate FDR
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correlated genes) in human liver cirrhosis and HCC from mixed etiologies and the pattern of gene expression in DIAMOND mice at 52 weeks NES, normalized enrichment
score; FDR, false discovery rate.
Research Articleexpression within the mouse transcriptome at 52 weeks demon-
strated significant concordance with cirrhosis of poor prognosis
(FDR <0.001) (Fig. 5F).
Development of HCC in DIAMOND mice
HCC developed in 89% of mice between weeks 32–52. There were
3 or more foci of tumors in each mouse (Figs. 2A, 6A and
Supplementary Table 4). All mice had foci of well-differentiated
HCC and 40% had poorly differentiated HCC. Also, hepatic
adenomas (Supplementary Fig. 6), some with foci of HCC within
them, were noted in 25% of the mice. At a transcriptomic level,
the HCC transcriptome was related to the S1 or S2 subclasses of
human HCC [23] (FDR: 0.013 and 0.014 respectively) (Fig. 6B).
Compared to surrounding non-tumorous liver in mice on WD
SW, the HCC transcriptome demonstrated activation of several
pathways related to nitrogen and amino acid metabolism,
oxidative stress signaling, inflammation and cell adhesion-
extracellular matrix remodeling (Fig. 6C–G). Functional process
network analysis (Fig. 6G and Supplementary Fig. 7) revealed
changes related to progesterone signaling, bile acid regulation
of lipid metabolism, hypoxia and oxidative stress, signal
transduction-ESR1 and modulation of apoptosis induced by
external signals by estrogen.584 Journal of Hepatology 201The B6/129 strain is distinct from the parent strains with respect to
recapitulating the NAFLD phenotype
Pure 129S1/SvImJ (S129) or C57BL/6J (B6) mice were fed WD SW
diet for 16–22 weeks and compared to the B6/129 mice (Fig. 7A).
In contrast to the B6/129 mice, both S129 and B6 mice fed WD
SW for 16–22 weeks remained insulin sensitive with a marked
drop in glucose levels following insulin administration similar
to CD NW-fed mice (Fig. 7B). Also, the S129 mice had less hep-
atomegaly and significantly lower LDL-c and total cholesterol
levels compared to B6/129 mice on the combination diet
(Fig. 7A and Supplementary Table 5).
Although WD SW feeding induced similar lobular inflamma-
tion and hepatocyte ballooning in all three mouse strains at 16–
22 weeks, steatosis was lower in S129 mice and there was a trend
for decreased fibrosis as well (Fig. 7D). As a consequence, WD SW-
fed S129 had a significantly lower NAS and Steatosis-Activity-
Fibrosis Score (SAF). The pure B6 mice developed extensive
macrovesicular steatosis by 22 weeks, but significantly less fibro-
sis as compared to B6/129 (Fig. 7C, D). While a longer duration of
feeding up to 52 weeks induced greater fibrosis in the pure B6
mice, none of these mice developed any tumors (Supplementary
Fig. 8). These results are consistent with the concept that
B6/129 strain are more insulin resistant, develop faster6 vol. 65 j 579–588
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JOURNAL OF HEPATOLOGYsteatohepatitis and HCC compared to the B6 mice. These changes
occurred despite a similar decrease in n3- and n6-
polyunsaturated fatty acids in all three strains (Fig. 7E).
To further gain insights into the differences between the B6 vs.
B6/129 mice, their full hepatic transcriptomes on WD SW were
compared in an unbiased manner at week 52. The B6/129 mice
had significantly greater activation of multiple pathways that
are known to be relevant for both NASH and oncogenesis. Cell
adhesion/cell matrix interactions, regulation of angiogenesis,
ECM remodeling, unfolded protein response, insulin signaling
and bile acid regulation of lipid metabolism related networks
were all upregulated in B6/129 mice compared to the B6 strain
(Supplementary Figs. 9 and 10). Interestingly, both collagen IV-
osteopontin-FAK1 network (Supplementary Table 6), as well as
an activin A-MMP-2-syntenin 2 network, both of which have
been associated with HCC development in humans [25–29], were
upregulated in B6/129 mice as compared to B6 after 52 weeks of
WD SW diet. Collectively, these results indicate that the crossed
mouse background B6/129 fed a WD SW constitute a faster and
more powerful model than the pure B6 mouse to recreate allJournal of Hepatology 201biochemical and histological parameters and HCC development
as seen in human NASH.Discussion
Animal models of human disease are an important element of
translational science required to better model the disease at a
molecular level, identify targets for therapeutics and for preclin-
ical testing of specific compounds before embarking on expensive
human clinical trials. To meet these needs, such models should
come as close to human disease as possible. In the context of
NASH, models should display all of the physiological, metabolic,
histological and clinical endpoints of human NASH.
We here describe a mouse model (DIAMOND) where fatty
liver disease was induced by caloric excess as occurs in most
humans with NASH. Upon initiation of WD SW, the mice gained
weight, became insulin resistant and developed dyslipidemia.
They also sequentially developed steatosis, steatohepatitis and
increasing fibrosis progressing to bridging fibrosis. It is6 vol. 65 j 579–588 585
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Fig. 7. Only the B6/129 background mice, but not the parent strains C57BL/6J (B6) or 129 S1/SvImJ (S129) fed a high fructose/glucose, high fat Western diet (WD SW)
for 16–22 weeks depicts the full phenotypic, biological and histological parameters associated with human NAFLD. C57BL/6J (B6), 129 S1/SvImJ (S129) or B6/129 mice
were fed for 16–22 weeks either a chow diet (CD NW) or a high fructose/sucrose, high fat Western diet (WD SW). (A) Gross liver pictures of WD SW-fed mice for
16–22 weeks, (B) insulin tolerance test (ITT), (C) representative liver sections stained with hematoxylin-eosin (H&E) (a, c, e) or Picrosirius Red (b, d, f) are shown (original
magnification, 10), (D) Histology score for steatosis, hepatocyte ballooning, lobular inflammation, NAFLD activity score, fibrosis and steatosis-activity-fibrosis score. Data
represent mean ± SEM for 4–6 mice per CD NW group and 7–13 mice per WD SW group; ⁄⁄⁄p <0.001, ⁄⁄p <0.01, ⁄p <0.05 WD SW B6/129 vs. WD SW B6 or WD SW S129. (E)
Liver n3- and n6-polyunsaturated fatty acids (PUFAs) were measured from B6/129 mice fed a chow diet (CD NW) or high fructose/glucose, high fat Western Diet (WD SW)
for 8, 16–24 and 52 weeks as described in the Supplementary materials and methods section. Data represent mean ± SEM for 4 mice per group; ⁄p <0.05 WD SW vs. CD NW.
Research Articleremarkable that, given the challenges in recapitulating human-
like steatohepatitis in mice, the mice developed florid steatohep-
atitis with ballooning and Mallory-Denk bodies based on a priori
criteria using the FLIP algorithm [30]. The mice also developed
spontaneous HCC without the need for additional manipulations.
At a transcriptomic level, there was a concordance in terms of the
pathways activated in humans with NAFLD and mice with corre-
sponding histologic phenotypes. Several key protein pathways
relevant to human NASH were also activated in these mice. These
mice therefore are similar to human disease in terms of initiation
with caloric excess, changes in metabolic status and lipid abnor-
malities, liver histology, development of progressive fibrosis and
HCC, changes in signaling pathways and activation of pathways
at a transcriptomic level.
Also, this model is distinct from both parent strains. The
129S1/SvImJ (S129) mice failed to develop both insulin resistance
and clear cut steatohepatitis. While the C57BL/6J (B6) mice even-
tually develop insulin resistance, they take a longer time to
develop this hallmark of the metabolic syndrome. Also, their his-
tology is milder and they do not develop HCC. At a molecular
level, there was a substantially greater activation of cell stress586 Journal of Hepatology 201and oncogenic pathways relevant for human disease in the
B6/129 mice. The genetic basis for this predilection for HCC is
an important question and future studies may provide some
novel information on HCC development following prolonged lipo-
toxic stress.
While there were many similarities between the DIAMOND
model andhumanNASH, it is also recognized that therewere some
dissimilarities. A large proportion of the mice developed sponta-
neous HCC while it is known that only a small proportion of
afflicted humans develop HCC [31]. As withmost othermicemod-
els, this model does not develop significant atherosclerosis as seen
in obese humans with NAFLD [31]. Also, fully established cirrhosis
was not commonly seen byweek 52. It is possible that further diet-
ary manipulation or knocking in the mutant human PNPLA3 gene
may accelerate fibrosis but remains a topic of future studies.
We anticipate that the DIAMOND mice could serve as a tool to
study several scientific questions in the future. These include
NASH, hepatic fibrosis and potentially HCC. The observed
decrease in steatosis despite maintained insulin resistance in
advanced disease recapitulates what is seen in humans and sets
the stage to study this phenomenon mechanistically. It is unlikely6 vol. 65 j 579–588
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to be due to weight loss, which appears to coincide clinically with
onset of HCC, because the animals remain insulin resistant. Also,
the development of bridging fibrosis in this model renders it
more relevant model to study NASH-related fibrosis rather than
traditional bile duct ligation or thioacetamide models. This model
may additionally serve as another tool to understand the genetics
of NASH especially with in depth analysis of the parent strains
and the crossed strain in our model. Changes in the microbiome,
as observed in human disease, remained to be evaluated in the
DIAMOND model to further permit the study of diet-
microbiome interactions and their relationship to NASH. The
authors look forward to future scientific endeavors and collabora-
tions to tackle these interesting questions.
It is important to note that this model was not meant to and
nor does it provide a novel unique mechanism for disease devel-
opment that is distinct from all existing models. Rather, it reca-
pitulates the physiological, metabolic, histological aspects of
human NASH in the same model along with strong concordance
with human disease with respect to changes within the transcrip-
tome and activation of pathways known to be relevant for NASH.
In summary, this DIAMOND recapitulates the various pheno-
types of NAFLD and their associated metabolic and underlying
molecular characteristics. It is hoped that it will serve as a rele-
vant model to identify therapeutic targets, model disease pro-
gression and test preventive and therapeutic approaches
against NASH, hepatic fibrosis and HCC.Financial support
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